Federal circuit denied to rehear the celebrex patent dispute

Federal Appeals court has denied to rehear the March decision which prevents Teva from marketing generic version of the pain killer drug celebrex till May 30, 2014.

Both Pfizer and Teva has asked the federal circuit for rehearing on its split ruling in March that held US5760068 invalid and reversing the district court decision w.r.t '068 patent while affirming the district court decision that Teva infringed both US5466823 and US5563165 expiring on May 30, 2014.